First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. [electronic resource]
Producer: 20170825Description: 142-150 p. digitalISSN:- 1879-0852
- Adult
- Aged
- Aged, 80 and over
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Indoles -- adverse effects
- Male
- Middle Aged
- Neoplasms -- drug therapy
- Protein Kinase Inhibitors -- adverse effects
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins c-met -- antagonists & inhibitors
- Receptor, Fibroblast Growth Factor, Type 1 -- antagonists & inhibitors
- Thiazolidinediones -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.